Clinical efficacy of daratumumab monotherapy in patients with ...

The most common (≥20%) TEAEs included fatigue, nausea, anemia, back pain, cough, upper respiratory tract infection, thrombocytopenia, and neutropenia.

Clinical efficacy of daratumumab monotherapy in patients ... - PubMed

The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was previously reported.

A pooled analysis of 2 daratumumab trials showed no new safety signals, an overall response rate of 31%, and deep and durable responses.

Clinical Efficacy of Daratumumab Monotherapy in Patients with ...

In two clinical studies (NCT00574288 [GEN501] and NCT01985126 [Sirius]), DARA monotherapy showed remarkable clinical activity and was well ...

Paper: Clinical Efficacy of Daratumumab Monotherapy in Patients ...

29 Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma Clinically Relevant ...

Daratumumab monotherapy in patients with heavily pretreated ...

Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a ...

Daratumumab monotherapy in patients with treatment-refractory ...

Daratumumab monotherapy showed substantial clinical activity, with an ORR of 29%, and was well tolerated in patients with multiple myeloma who ...

Efficacy of daratumumab monotherapy in real-world heavily ...

Daratumumab monotherapy has significant activity and good tolerance in heavily pretreated RRMM patients. Introduction. Multiple myeloma (MM) is the third most ...

Clinical efficacy of daratumumab monotherapy in patients with ...

In this pooled data set, daratumumab 16 mg/kg monotherapy demonstrated rapid, deep, and durable responses, with a clinical benefit that extended to patients ...

Daratumumab monotherapy for patients with intermediate-risk or ...

The co-primary endpoint of CR rate of >15% was not met at the time of clinical cutoff, which suggests that single-agent daratumumab may not be ...

Daratumumab monotherapy in patients with treatment-refractory ...

Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in ...

Clinical efficacy of daratumumab, pomalidomide, and ...

Importantly, even in patients who were refractory to both DARA and POM, DARA-POM-D attained an ORR of nearly 35%. This response rate is ...

Clinical Efficacy of Daratumumab Monotherapy in Patients with ...

ORR was similar across prespecified subgroups which included age, ISS stage, number of prior therapies, and refractory status. Conclusions : ...

Daratumumab Monotherapy in Heavily Pretreated Asian Patients ...

Background/Aim: Daratumumab is a promising novel agent for relapsed/refractory multiple myeloma (RRMM). However, there are limited data on its efficacy and ...

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma.

Clinical efficacy of daratumumab monotherapy in patients with ...

... are shown. - "Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma."

Clinical efficacy of daratumumab monotherapy in patients with ...

Request PDF | Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma | Key Points A pooled ...

Dose-dependent efficacy of daratumumab (DARA) as monotherapy ...

Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). Authors: Henk M. Lokhorst, Jacob ...

a phase 1, dose-escalation study (MMY1003) - SpringerLink

Daratumumab monotherapy demonstrated favorable safety and efficacy in relapsed/refractory multiple myeloma (RRMM) patients in the global phase 1/2 GEN501 and ...

Daratumumab-Based Therapeutic Approaches and Clinical ...

This retrospective review analyzed 112 patients who received daratumumab between 2012 and 2020. Tolerability, and efficacy based on prior lines (PL) of therapy ...